l-Sulpiride in young and elderly negative schizophrenics

Clinical and pharmacokinetic variables

Massimo C. Mauri, Patrizia Leva M., Teresa Coppola, Carlo A. Altamura

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

1. Clinical activity, tolerability and kinetic profile of L-sulpiride (200-300 mg/die p.o.) in relation to age, in 14 chronic schizophrenic in patients diagnosed according to DSM III-R, typed as negative forms, were studied. 2. The drug showed Its efficacy in negative forms of schizophrenia, without any significant difference between negative and positive symptoms even if productive symptom scores were quite low already in pre-treatment condition. 3. No more side effects (anticholinergic and extrapyramidal) in elderly patients compared to young/adult ones were reported. 4. No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t 1 2, AUC, Cmax, Tmax, Vd and CI), after acute and multiple dosing, were observed.

Original languageEnglish
Pages (from-to)355-366
Number of pages12
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume18
Issue number2
DOIs
Publication statusPublished - 1994

Fingerprint

Sulpiride
Pharmacokinetics
Young Adult
Cholinergic Antagonists
Diagnostic and Statistical Manual of Mental Disorders
Area Under Curve
Schizophrenia
Pharmaceutical Preparations
Therapeutics

Keywords

  • elderly
  • L-sulpiride
  • negative schizophrenia
  • pharmacokinetics

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{d9668d4f88f844e783e137ec739ad869,
title = "l-Sulpiride in young and elderly negative schizophrenics: Clinical and pharmacokinetic variables",
abstract = "1. Clinical activity, tolerability and kinetic profile of L-sulpiride (200-300 mg/die p.o.) in relation to age, in 14 chronic schizophrenic in patients diagnosed according to DSM III-R, typed as negative forms, were studied. 2. The drug showed Its efficacy in negative forms of schizophrenia, without any significant difference between negative and positive symptoms even if productive symptom scores were quite low already in pre-treatment condition. 3. No more side effects (anticholinergic and extrapyramidal) in elderly patients compared to young/adult ones were reported. 4. No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t 1 2, AUC, Cmax, Tmax, Vd and CI), after acute and multiple dosing, were observed.",
keywords = "elderly, L-sulpiride, negative schizophrenia, pharmacokinetics",
author = "Mauri, {Massimo C.} and M., {Patrizia Leva} and Teresa Coppola and Altamura, {Carlo A.}",
year = "1994",
doi = "10.1016/0278-5846(94)90067-1",
language = "English",
volume = "18",
pages = "355--366",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - l-Sulpiride in young and elderly negative schizophrenics

T2 - Clinical and pharmacokinetic variables

AU - Mauri, Massimo C.

AU - M., Patrizia Leva

AU - Coppola, Teresa

AU - Altamura, Carlo A.

PY - 1994

Y1 - 1994

N2 - 1. Clinical activity, tolerability and kinetic profile of L-sulpiride (200-300 mg/die p.o.) in relation to age, in 14 chronic schizophrenic in patients diagnosed according to DSM III-R, typed as negative forms, were studied. 2. The drug showed Its efficacy in negative forms of schizophrenia, without any significant difference between negative and positive symptoms even if productive symptom scores were quite low already in pre-treatment condition. 3. No more side effects (anticholinergic and extrapyramidal) in elderly patients compared to young/adult ones were reported. 4. No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t 1 2, AUC, Cmax, Tmax, Vd and CI), after acute and multiple dosing, were observed.

AB - 1. Clinical activity, tolerability and kinetic profile of L-sulpiride (200-300 mg/die p.o.) in relation to age, in 14 chronic schizophrenic in patients diagnosed according to DSM III-R, typed as negative forms, were studied. 2. The drug showed Its efficacy in negative forms of schizophrenia, without any significant difference between negative and positive symptoms even if productive symptom scores were quite low already in pre-treatment condition. 3. No more side effects (anticholinergic and extrapyramidal) in elderly patients compared to young/adult ones were reported. 4. No significant differences between young/adult and elderly patients for the various pharmacokinetic parameters (t 1 2, AUC, Cmax, Tmax, Vd and CI), after acute and multiple dosing, were observed.

KW - elderly

KW - L-sulpiride

KW - negative schizophrenia

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0028256469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028256469&partnerID=8YFLogxK

U2 - 10.1016/0278-5846(94)90067-1

DO - 10.1016/0278-5846(94)90067-1

M3 - Article

VL - 18

SP - 355

EP - 366

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -